During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.

Participants in the study will receive either duvakitug or a placebo through a subcutaneous injection, which is a shot administered just under the skin. This is a randomized study, meaning participants are assigned to a group by chance, and it is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The study involves monitoring the condition over a period of time to observe how the body responds to the medication.

The study is divided into different parts. People who join this particular part of the study will be those who have already shown improvement after earlier treatment and have completed certain examinations. The study will look at whether Duvakitug can help keep the condition in a state where symptoms are minimal or absent, which is called remission. During the study, doctors will check the condition of the intestine using an examination that looks inside the bowel, and they will also assess symptoms such as bowel movements, bleeding, and abdominal pain. The study will also look at whether people can stop using steroid medications while maintaining good control of their condition.

Throughout the study, participants will be monitored for any side effects or unwanted reactions to the treatment. The study will measure various aspects of the disease and how it affects daily life, including fatigue levels, quality of life, and the need for hospital care related to ulcerative colitis. Blood samples will be taken to measure the amount of Duvakitug in the body and to check if the body develops any immune response to the medication. The study will also include a longer extension period for people who complete the main part of the study, allowing for continued observation of the medication’s effects and safety over time.

The purpose of this study is to assess how well Duvakitug works as an initial treatment for moderately to severely active Ulcerative Colitis compared to placebo. The study will look at whether the medication can help reduce symptoms and inflammation in the intestines. This is called an induction study, which means it focuses on the first phase of treatment to see if the medication can bring the disease under control.

The study will measure several outcomes to determine if the treatment is working. The main outcome will be the proportion of participants who achieve clinical remission, which means their symptoms have improved significantly or disappeared. Other outcomes include improvements in the appearance of the intestine lining as seen during examination, reduction in symptoms like bowel urgency and abdominal pain, improvements in quality of life, and whether participants need to be hospitalized due to their condition. The study will also monitor any side effects and measure the levels of the medication in the blood over time. The treatment period will last up to 24 weeks.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this study is to determine whether risankizumab is as effective as or more effective than vedolizumab for treating ulcerative colitis over a 48-week period. Participants in this study will have already tried other conventional treatments such as aminosalicylates (anti-inflammatory drugs), steroids, or immunomodulators without adequate relief of their symptoms.

During the study, participants will be randomly assigned to receive either risankizumab or vedolizumab. The study will monitor improvements in the intestinal lining through endoscopy (a procedure where a small camera is used to examine the inside of the colon) and track symptom improvement including stool frequency and rectal bleeding. This is an open-label study, meaning both the healthcare providers and participants will know which medication is being administered.

The purpose of the study is to evaluate how well lutikizumab works in reducing the symptoms of ulcerative colitis and to monitor any side effects. The study will involve both intravenous (IV) and subcutaneous (SC) forms of lutikizumab, meaning the medication will be administered either through a vein or under the skin. Participants will be monitored over a period of time to assess changes in their disease activity and any adverse events they may experience.

Throughout the study, participants will undergo regular assessments to track their progress. The study aims to determine the percentage of participants who show improvement in their condition by week 12. This includes looking at endoscopic improvement, which involves examining the inside of the colon, as well as clinical remission and response, which refer to the reduction or disappearance of symptoms. The study is expected to last for up to 52 weeks, providing valuable information on the long-term effects of lutikizumab in treating ulcerative colitis.

The purpose of the study is to evaluate how effective and safe VTX002 is for people with moderately to severely active Ulcerative Colitis. Participants in the study will be randomly assigned to receive either the VTX002 tablets or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for about 13 weeks, during which time participants will take the tablets orally. Throughout the study, the health and progress of the participants will be closely monitored to assess the treatment’s impact on their condition.

The study aims to see if VTX002 can help achieve clinical remission, which means reducing the symptoms to a minimal level, and to observe any improvements in the condition of the colon as seen through endoscopic examinations. The trial will also look at other aspects such as symptom relief and tissue healing in the colon. This research is important for finding new ways to manage and treat Ulcerative Colitis effectively.

Participants in the study will receive Etrasimod Arginine and will be monitored for any side effects or changes in their health. The study will track the occurrence of any new health issues that arise during the treatment, as well as any changes in laboratory test results and vital signs. The study will also look at how many participants experience an improvement in their symptoms over time.

The study will continue for several years, allowing researchers to gather comprehensive data on the long-term use of Etrasimod Arginine. Participants will have regular check-ups to monitor their condition and the effects of the medication. This research aims to provide valuable information on the safety and effectiveness of Etrasimod Arginine for treating Ulcerative Colitis.

Participants in the study will be randomly assigned to receive either Tovinontrine or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will last for 12 weeks, during which time the effects of the medication on certain heart-related markers in the blood will be monitored. These markers include NT-proBNP, a substance that is often elevated in heart failure, and cGMP, which is related to heart function. The study aims to find the best dose of Tovinontrine that can help improve these markers.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving Tovinontrine and who is receiving the placebo. This helps ensure that the results are unbiased and reliable. The ultimate goal is to determine if Tovinontrine can be a safe and effective treatment option for people with chronic heart failure with reduced ejection fraction.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.

The purpose of this study is to determine if long-term treatment with mirikizumab can help manage symptoms in patients with moderately to severely active ulcerative colitis. Participants in this study will receive mirikizumab as a solution for injection. The study will monitor the participants over time to assess the medication’s effectiveness and safety. This includes observing how many participants achieve clinical remission, which means a significant reduction or disappearance of symptoms.

Throughout the study, researchers will also look at other factors, such as the percentage of participants who achieve endoscopic remission, which is a reduction in visible inflammation during a medical examination of the colon. Additionally, the study will track the number of hospitalizations and surgeries related to ulcerative colitis, as well as changes in quality of life scores. The study aims to provide valuable information on the long-term benefits and safety of mirikizumab for individuals living with ulcerative colitis.

Participants in the study will be randomly assigned to receive either the MORF-057 capsule or a placebo, which looks like the treatment but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations about the treatment’s effectiveness.

The study will last for up to 52 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The main goal is to see how many participants achieve clinical remission by the 12th week, with additional observations continuing throughout the study period to assess longer-term effects and safety. This research is important for understanding how MORF-057 might help people with moderately to severely active ulcerative colitis manage their condition more effectively.

The purpose of the study is to determine if Inclisiran can reduce the risk of serious heart problems, such as heart attacks, strokes, or the need for urgent procedures to restore blood flow to the heart. The study will be conducted over a period of time, during which participants will receive regular injections of the medication or placebo and will be monitored for any heart-related events. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Participants will be closely observed throughout the study to track the time it takes for any major heart events to occur. The study will also look at other outcomes, such as the time to cardiovascular death and overall mortality. The goal is to gather information on the safety and effectiveness of Inclisiran in preventing heart-related issues in people who are at high risk but have not yet had a major cardiovascular event.

The purpose of the study is to evaluate the safety and effectiveness of these targeted therapies. Participants will receive either one of the study medications or a placebo. The study will last for a period of up to 24 weeks, during which participants will receive regular treatments and undergo various health assessments to monitor their response to the medication. The goal is to see if these treatments can help achieve endoscopic remission, which means reducing the visible signs of inflammation in the digestive tract, and clinical remission, which involves a significant reduction in symptoms.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how well the treatments work. This research aims to provide new insights into managing Crohn’s Disease and improving the quality of life for those affected by this condition.

Participants in the study will receive either duvakitug or a placebo through a subcutaneous injection, which is a method of delivering medication just under the skin. This is an induction study, meaning the goal is to determine how well the treatment can quickly reduce active symptoms and inflammation. The study uses a randomized and double-blind approach, which means participants are assigned to groups by chance, and neither the participants nor the researchers know which specific treatment is being administered during the course of the study.

Participants in the study will be randomly assigned to receive either Selatogrel or a Selatogrel matching placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will follow participants over a period to observe the occurrence of death or another heart attack after they have self-administered the treatment.

The study will also monitor for any safety concerns, such as bleeding events, that may occur within two days after taking the treatment. Additionally, researchers will look at other outcomes like hospital visits for heart failure within 30 days after treatment. This trial aims to provide valuable information on the potential benefits and risks of using Selatogrel for individuals at risk of having another heart attack.